Literature DB >> 14191102

CYTOSINE ARABINOSIDE (CA) AND OTHER NUCLEOSIDES IN HERPES VIRUS INFECTIONS.

G E UNDERWOOD, C A WISNER, S D WEED.   

Abstract

Entities:  

Keywords:  ANTIVIRAL AGENTS; EXPERIMENTAL LAB STUDY; IDOXURIDINE; KERATITIS, DENDRITIC; NUCLEOSIDES; OINTMENTS; PHARMACOLOGY; RABBITS; STATISTICS; THYMIDINE

Mesh:

Substances:

Year:  1964        PMID: 14191102     DOI: 10.1001/archopht.1964.00970020505014

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


× No keyword cloud information.
  7 in total

1.  Herpesvirus hominis infection in patients with myeloproliferative and lymphoproliferative disorders.

Authors:  D L Aston; A Cohen; M A Spindler
Journal:  Br Med J       Date:  1972-11-25

2.  Synergistic effect of herpes simplex virus and cytosine arabinoside on human chromosomes.

Authors:  F J O'Neill; F Rapp
Journal:  J Virol       Date:  1971-05       Impact factor: 5.103

3.  Severe generalized primary herpes treated with cytarabine.

Authors:  B E Juel-Jensen
Journal:  Br Med J       Date:  1970-04-18

4.  Antiviral activity of arabinosylthymine in herpesviral replication: mechanism of action in vivo and in vitro.

Authors:  J F Aswell; G P Allen; A T Jamieson; D E Campbell; G A Gentry
Journal:  Antimicrob Agents Chemother       Date:  1977-08       Impact factor: 5.191

5.  Differential effect of arabinofuranosylthymine of the replication of human herpesviruses.

Authors:  R L Miller; J P Iltis; F Rapp
Journal:  J Virol       Date:  1977-09       Impact factor: 5.103

6.  Susceptibility of herpesviruses to cytosine arabinoside: standardization of susceptibility test procedure and relative resistance of herpes simplex type 2 strains.

Authors:  M Fiala; A Chow; L B Guze
Journal:  Antimicrob Agents Chemother       Date:  1972-04       Impact factor: 5.191

7.  Cytosine arabinoside therapy for herpes simplex encephalitis--clinical experience with six patients.

Authors:  A W Chow; A Roland; M Fiala; W Hryniuk; M L Weil; J S Geme; L B Guze
Journal:  Antimicrob Agents Chemother       Date:  1973-03       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.